Barnett International, a division of PAREXEL International Corporation (Nasdaq:PRXL), has announced the release of New Drug Development: A Regulatory Overview, which features what is now one of the most comprehensive analyses of the drug regulatory process within the United States, the world’s most lucrative pharmaceutical market.

PAREXEL International Corporation (Nasdaq: PRXL), one of the world’s largest bio/pharmaceutical services companies, today announced that it has entered into a strategic collaboration with the Korea Institute of Industrial Technology (KITECH).

- Q1 operating margin of 7.3% drives EPS growth of approximately 17% -

Enhances the Company's patient and investigator recruitment capabilities -

PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter 2005 financial results on Wednesday, October 20, 2004 before the opening of trading.

Providing comprehensive drug development and management and organizational effectiveness consulting

PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Antoni A. Piergies, MD, MSEE as Vice President, Clinical Pharmacology and Director of PAREXEL’s Clinical Pharmacology Research Unit (CPRU) located within the Harbor Hospital Center in Baltimore, Maryland.

PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Kurt Brykman as President, PAREXEL Consulting.

Barnett Educational Services, a division of PAREXEL International Corporation (Nasdaq: PRXL), has announced the release of State-by-State Clinical Trial Requirements Reference Guide.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that its Board of Directors approved a stock repurchase program authorizing the repurchase of up to $20 million of the Company’s common stock.

-Strategic alliance designed to develop clinical services in online community-

Company achieves Q4 operating margin of 7.3%, and EPS of $0.24

PAREXEL International Corporation (Nasdaq: PRXL) will release Fourth Quarter and Fiscal 2004 financial results on Tuesday, August 3, 2004 before the opening of trading.

-Leading Clinical Trials Management System continues to surpass traditional limits-

PAREXEL International Corporation (Nasdaq: PRXL) announced today that it will discuss forward-looking earnings expectations for the fourth quarter of Fiscal Year 2004 (ending June 30, 2004), for Fiscal 2004 in its entirety, for Calendar 2004 and for Fiscal 2005 at its Investor Day being held tomorrow in New York City.

Barnett International, a division of PAREXEL International Corporation (Nasdaq: PRXL), has announced the release of Good Clinical Practice: A Question & Answer Reference Guide 2004 (Second Edition).

Barnett International, a division of PAREXEL International Corporation (Nasdaq:PRXL), has announced the release of the 2004/2005 edition of PAREXEL’s Pharmaceutical R&D Statistical Sourcebook, the leading compendium on emerging pharma/biotech R&D trends, industry performance metrics, drug/biotech product pipeline, and regulatory data.

Collaboration designed to enhance investigator identification to reduce the time and cost of clinical trials

PAREXEL International Corporation (Nasdaq: PRXL) is again pleased to offer a Research Grant in memory of Professor Werner M. Herrmann, M.D.

PAREXEL International Corporation (Nasdaq: PRXL) today issued a press release to correct a computational error in its forward-looking GAAP diluted earnings per share guidance for Fiscal 2004 and Calendar 2004.

Company enters exclusive agreement with Synchron Research

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter ended March 31, 2004.

Phase I/IIa Business Specializes in Cardiovascular, CNS, and Infectious Disease Studies

PAREXEL International Corporation (Nasdaq: PRXL), one of the largest contract biopharmaceutical outsourcing organizations in the world, announced today that it will broadcast its Investor Day live over the Internet on Wednesday, June 2nd from 8:30 a.m. to 12:30 p.m. ET.

Advanced clinical trials management curriculum offered

Perceptive Informatics, Inc., a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), and a provider of innovative technology-based solutions designed to accelerate drug development, today announced the release of its second generation Virtual Panel System (VPS).

PAREXEL International Corporation (Nasdaq: PRXL) will release Third Quarter FY 2004 financial results on Thursday, April 22, 2004 before the opening of trading.

Barnett Educational Services, a division of PAREXEL International Corporation (Nasdaq: PRXL), announces the release of the new reference manual, Part 11 and Drug Development

Barnett International, a division of PAREXEL International Corporation (Nasdaq: PRXL), announces the expansion of its drug development educational conference offerings in Europe.

-Web version of leading Clinical Trials Management System now available-

PAREXEL International Corporation (Nasdaq: PRXL) today announced that Herman Scholtz, MBChB, MMed, FCA (SA), has been appointed Vice President and Worldwide Head of the Company’s Clinical Pharmacology business.

Barnett International, a division of PAREXEL International Corporation (Nasdaq:PRXL), announced the release of the 2004 edition of Biologics Development

PAREXEL International Corporation (Nasdaq: PRXL), today announced that Richard V. Levy, PhD, has been named an Officer and Chair-elect of the PDA Board of Directors as a result of a vote of the PDA membership.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the UBS Warburg Global Healthcare Services Conference at The Plaza Hotel in New York City.

Earnings per share of $0.19 met consensus expectations